Travere Therapeutics, Inc.
TVTX
$17.92
$0.130.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 333.87M | 273.53M | 233.18M | 203.45M | 177.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 333.87M | 273.53M | 233.18M | 203.45M | 177.64M |
| Cost of Revenue | 220.38M | 225.88M | 225.24M | 224.93M | 233.50M |
| Gross Profit | 113.49M | 47.65M | 7.94M | -21.48M | -55.86M |
| SG&A Expenses | 284.17M | 272.73M | 264.12M | 258.21M | 260.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 504.55M | 498.62M | 489.36M | 483.14M | 493.89M |
| Operating Income | -170.68M | -225.09M | -256.18M | -279.69M | -316.25M |
| Income Before Tax | -169.10M | -225.93M | -320.51M | -348.70M | -383.09M |
| Income Tax Expenses | -97.00K | -32.00K | 120.00K | 260.00K | 356.00K |
| Earnings from Continuing Operations | -169.00 | -225.90 | -320.63 | -348.96 | -383.45 |
| Earnings from Discontinued Operations | -55.00K | -812.00K | -915.00K | -2.50M | 237.54M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.06M | -226.71M | -321.55M | -351.45M | -145.91M |
| EBIT | -170.68M | -225.09M | -256.18M | -279.69M | -316.25M |
| EBITDA | -120.54M | -178.61M | -212.63M | -238.74M | -275.06M |
| EPS Basic | -2.04 | -2.81 | -4.10 | -4.56 | -1.88 |
| Normalized Basic EPS | -1.26 | -1.73 | -2.01 | -2.20 | -2.49 |
| EPS Diluted | -2.04 | -2.81 | -4.10 | -4.56 | -1.88 |
| Normalized Diluted EPS | -1.26 | -1.73 | -2.01 | -2.20 | -2.49 |
| Average Basic Shares Outstanding | 338.19M | 326.74M | 315.52M | 308.89M | 307.42M |
| Average Diluted Shares Outstanding | 338.19M | 326.74M | 315.52M | 308.89M | 307.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |